{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:35:18Z","timestamp":1784892918126,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41429-019-0188-6","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T08:03:39Z","timestamp":1556265819000},"page":"600-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates"],"prefix":"10.1038","volume":"72","author":[{"given":"H. Selcuk","family":"Ozger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Cuhadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap Suzuk","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra","family":"Demirbas Gulmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Dizbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Guzel Tunccan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Kalkanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husniye","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Unaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"key":"188_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391\u2013400.","journal-title":"Lancet Infect Dis"},{"key":"188_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jhin.2017.11.014","volume":"98","author":"M Aydin","year":"2018","unstructured":"Aydin M, et al. Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections. J Hosp Infect. 2018;98:260\u20133.","journal-title":"J Hosp Infect"},{"key":"188_CR3","unstructured":"Organization WH. Central Asian and Eastern European Surveillance of Antimicrobial Resistance. Annu Rep. 2017."},{"key":"188_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ofid\/ofy293","volume":"6","author":"AC Gales","year":"2019","unstructured":"Gales AC, et al. Antimicrobial susceptibility of acinetobacter calcoaceticus-acinetobacter baumannii complex and stenotrophomonas maltophilia clinical isolates: results from the SENTRY Antimicrobial Surveillance Program (1997-2016). Open Forum Infect Dis. 2019;6:34\u201346.","journal-title":"Open Forum Infect Dis"},{"key":"188_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/cid\/ciy543","volume":"68","author":"A Bonell","year":"2019","unstructured":"Bonell A, et al. A systematic review and meta-analysis of ventilator-associated Pneumonia in adults in Asia: an analysis of national income level on incidence and etiology. Clin Infect Dis. 2019;68:511\u20138.","journal-title":"Clin Infect Dis"},{"key":"188_CR6","unstructured":"Resistance OWCAaEESoA. Central Asian and Eastern European Surveillance of Antimicrobial Resistance. Annu Rep. 2017."},{"key":"188_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/ja.2014.119","volume":"68","author":"X Zhang","year":"2015","unstructured":"Zhang X, Gu B, Mei Y, Wen Y, Xia W. Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004-2011. J Antibiot. 2015;68:115\u201320.","journal-title":"J Antibiot"},{"key":"188_CR8","doi-asserted-by":"crossref","unstructured":"Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2019;63 (1).","DOI":"10.1128\/AAC.01110-18"},{"key":"188_CR9","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1093\/jac\/dkx186","volume":"72","author":"S Vourli","year":"2017","unstructured":"Vourli S, Dafopoulou K, Vrioni G, Tsakris A, Pournaras S. Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2017;72:2528\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"188_CR10","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1093\/jac\/dkx322","volume":"72","author":"J Nowak","year":"2017","unstructured":"Nowak J, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72:3277\u201382.","journal-title":"J Antimicrob Chemother"},{"key":"188_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijantimicag.2014.10.002","volume":"45","author":"W Ni","year":"2015","unstructured":"Ni W, et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45:8\u201318.","journal-title":"Int J Antimicrob Agents"},{"key":"188_CR12","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3906\/sag-1601-38","volume":"47","author":"A But","year":"2017","unstructured":"But A, et al. Analysis of epidemiology and risk factors for mortality in ventilator-associated pneumonia attacks in intensive care unit patients. Turk J Med Sci. 2017;47:812\u20136.","journal-title":"Turk J Med Sci"},{"key":"188_CR13","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1128\/AAC.00436-16","volume":"60","author":"DM Livermore","year":"2016","unstructured":"Livermore DM, Mushtaq S, Warner M, Woodford N. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:3840\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"188_CR14","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57:5548\u201358.","journal-title":"Antimicrob Agents Chemother"},{"key":"188_CR15","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah M, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59:1802\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"188_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","volume":"51","author":"H Seifert","year":"2018","unstructured":"Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51:62\u20134.","journal-title":"Int J Antimicrob Agents"},{"key":"188_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, et al. Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152:224\u201332.","journal-title":"JAMA Surg"},{"key":"188_CR18","doi-asserted-by":"publisher","unstructured":"Solomkin JS, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections. Clin Infect Dis. 2018. \n                    https:\/\/doi.org\/10.1093\/cid\/ciy\/1029\n                    \n                  .","DOI":"10.1093\/cid\/ciy\/1029"},{"key":"188_CR19","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests f or Bacteria That Grow Aerobically; Approved St andard\u2014Ninth Edition. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute; 2012."},{"key":"188_CR20","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100. Wayne PCaLSI,. Performance Standards for Antimicrobial Susceptibility Testing. 28th edn. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018."},{"key":"188_CR21","first-page":"13859","volume":"8","author":"C Hou","year":"2015","unstructured":"Hou C, Yang F. Drug-resistant gene of blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 in Acinetobacter baumannii. Int J Clin Exp Med. 2015;8:13859\u201363.","journal-title":"Int J Clin Exp Med"},{"key":"188_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1128\/AAC.05289-11","volume":"56","author":"L Poirel","year":"2012","unstructured":"Poirel L, Bonnin RA, Nordmann P. Genetic features of the widespread plasmid coding for the Carbapenemase OXA-48. Antimicrob Agents Ch. 2012;56:559\u201362.","journal-title":"Antimicrob Agents Ch"},{"issue":"Pt 8","key":"188_CR23","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1099\/jmm.0.47206-0","volume":"56","author":"H Zhou","year":"2007","unstructured":"Zhou H, et al. Dissemination of imipenem-resistant Acinetobacter baumannii strains carrying the ISAba1 blaOXA-23 genes in a Chinese hospital. J Med Microbiol. 2007;56(Pt 8):1076\u201380.","journal-title":"J Med Microbiol"},{"key":"188_CR24","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/jac\/dkr226","volume":"66","author":"S Mushtaq","year":"2011","unstructured":"Mushtaq S, et al. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother. 2011;66:2002\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"188_CR25","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1128\/AAC.00679-07","volume":"52","author":"U Garza-Ramos","year":"2008","unstructured":"Garza-Ramos U, et al. Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. Antimicrob Agents Chemother. 2008;52:2943\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"188_CR26","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1093\/jac\/dkq352","volume":"65","author":"MR Gomez-Gil","year":"2010","unstructured":"Gomez-Gil MR, et al. Detection of KPC-2-producing Citrobacter freundii isolates in Spain. J Antimicrob Chemother. 2010;65:2695\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"188_CR27","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1128\/AAC.00285-06","volume":"50","author":"FM Kaczmarek","year":"2006","unstructured":"Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35\/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrob Agents Chemother. 2006;50:3396\u2013406.","journal-title":"Antimicrob Agents Chemother"},{"key":"188_CR28","unstructured":"National Antimicrobial Reistance Surveillance Report, Ministery of Health General Directrote of Public Health Department,Turkey. 2017."},{"key":"188_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cmi.2017.09.016","volume":"24","author":"T Amat","year":"2018","unstructured":"Amat T, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018;24:630\u20134.","journal-title":"Clin Microbiol Infect"},{"key":"188_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ijantimicag.2017.12.020","volume":"51","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51:535\u201347.","journal-title":"Int J Antimicrob Agents"},{"key":"188_CR31","doi-asserted-by":"publisher","first-page":"908 1","DOI":"10.1016\/j.cmi.2017.10.033","volume":"24","author":"CA Liang","year":"2018","unstructured":"Liang CA, et al. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018;24:908 1\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"188_CR32","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1128\/AAC.06187-11","volume":"56","author":"TH Grossman","year":"2012","unstructured":"Grossman TH, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56:2559\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"188_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.diagmicrobio.2017.12.013","volume":"91","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis. 2018;91:55\u201362.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"188_CR34","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1128\/AAC.00366-16","volume":"60","author":"ML Monogue","year":"2016","unstructured":"Monogue ML, Thabit AK, Hamada Y, Nicolau DP. Antibacterial efficacy of eravacycline in vivo against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother. 2016;60:5001\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"188_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, et al. Review of Eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76:567\u201388.","journal-title":"Drugs"},{"key":"188_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.5578\/mb.29176","volume":"50","author":"FS Beris","year":"2016","unstructured":"Beris FS, et al. Investigation of the frequency and distribution of beta-lactamase genes in the clinical isolates of Acinetobacter baumannii collected from different regions of Turkey: a multicenter study. Mikrobiyoloji Bul. 2016;50:511\u201321.","journal-title":"Mikrobiyoloji Bul"},{"key":"188_CR37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.ijantimicag.2017.01.028","volume":"49","author":"S Pournaras","year":"2017","unstructured":"Pournaras S, et al. Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study. Int J Antimicrob Agents. 2017;49:749\u201353.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"188_CR38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijantimicag.2018.10.020","volume":"53","author":"Jin Wang","year":"2019","unstructured":"Wang J, Niu H, Wang R, Cai Y. Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018; 53.383\u2013400.","journal-title":"International Journal of Antimicrobial Agents"},{"key":"188_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874285801711010063","volume":"11","author":"M Mohammadi","year":"2017","unstructured":"Mohammadi M, et al. Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii: a systematic review and meta-analysis. Open Microbiol J. 2017;11:63\u201371.","journal-title":"Open Microbiol J"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0188-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0188-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0188-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:32:02Z","timestamp":1684603922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-019-0188-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1038\/s41429-019-0188-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/552547","asserted-by":"object"}]},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"7 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}